Raras
Buscar doenças, sintomas, genes...
Doença monogênica com epilepsia
ORPHA:166472PCDT · SUSDOENÇA RARA

Genética médica ou genética clínica é a especialidade que lida com o diagnóstico, tratamento e controle dos distúrbios genéticos e hereditários. É uma área que enfoca não só o paciente mas também toda a família, principalmente por meio do aconselhamento genético.

Mantido por Agente Raras·Colaborar como especialista →

Introdução

O que você precisa saber de cara

📋

Doença monogênica rara caracterizada por epilepsia, distúrbios neurológicos como instabilidade postural e do sistema nervoso, e achados como duplicação renal e displasia ungueal. Associada a mutações em genes como TDP2, TNK2 e SCN8A.

🏥
SUS: Cobertura mínimaScore: 30%
PCDT disponível
Você se identifica com essa condição?
O Raras está aqui pra te apoiar — com ou sem diagnóstico

Encontrou um erro ou informação desatualizada? Sugira uma correção →

Entender a doença

Do básico ao detalhe, leia no seu ritmo

Preparando trilha educativa...

Sinais e sintomas

O que aparece no corpo e com que frequência cada sintoma acontece

Partes do corpo afetadas

🧠
Neurológico
94 sintomas
😀
Face
47 sintomas
🦴
Ossos e articulações
39 sintomas
👁️
Olhos
36 sintomas
❤️
Coração
22 sintomas
📏
Crescimento
17 sintomas

+ 182 sintomas em outras categorias

Características mais comuns

Distúrbio da marcha
Instabilidade postural
EEG com espículas focais temporais
Duplicação da pelve renal
Bossas frontais
Anormalidade do sistema nervoso
503sintomas
Sem dados (503)

Os sintomas variam de pessoa para pessoa. Abaixo estão as 503 características clínicas mais associadas, ordenadas por frequência.

Distúrbio da marchaGait disturbance
Instabilidade posturalPostural instability
EEG com espículas focais temporaisEEG with temporal focal spikes
Duplicação da pelve renalDuplication of renal pelvis
Bossas frontaisFrontal bossing

Linha do tempo da pesquisa

Publicações por ano — veja quando o interesse científico cresceu
Anos de pesquisa8
Últimos 10 anos200publicações
Pico202230 papers
Linha do tempo
20202018Hoje · 2026🧪 2009Primeiro ensaio clínico📈 2022Ano de pico
Publicações por ano (últimos 10 anos)

Encontrou um erro ou informação desatualizada? Sugira uma correção →

Genética e causas

O que está alterado no DNA e como passa nas famílias

Genes associados

24 genes identificados com associação a esta condição.

TDP2Tyrosyl-DNA phosphodiesterase 2Disease-causing germline mutation(s) inTolerante
FUNÇÃO

DNA repair enzyme that can remove a variety of covalent adducts from DNA through hydrolysis of a 5'-phosphodiester bond, giving rise to DNA with a free 5' phosphate. Catalyzes the hydrolysis of dead-end complexes between DNA and the topoisomerase 2 (TOP2) active site tyrosine residue. The 5'-tyrosyl DNA phosphodiesterase activity can enable the repair of TOP2-induced DNA double-strand breaks/DSBs without the need for nuclease activity, creating a 'clean' DSB with 5'-phosphate termini that are re

LOCALIZAÇÃO

NucleusNucleus, PML bodyNucleus, nucleolusCytoplasm

VIAS BIOLÓGICAS (1)
Nonhomologous End-Joining (NHEJ)
MECANISMO DE DOENÇA

Spinocerebellar ataxia, autosomal recessive, 23

A form of spinocerebellar ataxia, a clinically and genetically heterogeneous group of cerebellar disorders due to degeneration of the cerebellum with variable involvement of the brainstem and spinal cord. SCAR23 patients manifest epilepsy, intellectual disability, and gait ataxia.

EXPRESSÃO TECIDUAL(Ubíquo)
Intestino delgado
57.6 TPM
Cérebro - Hemisfério cerebelar
47.5 TPM
Cólon transverso
46.9 TPM
Próstata
44.4 TPM
Linfócitos
41.8 TPM
OUTRAS DOENÇAS (1)
spinocerebellar ataxia, autosomal recessive 23
HGNC:17768UniProt:O95551
TNK2Activated CDC42 kinase 1Candidate gene tested inTolerante
FUNÇÃO

Non-receptor tyrosine-protein and serine/threonine-protein kinase that is implicated in cell spreading and migration, cell survival, cell growth and proliferation. Transduces extracellular signals to cytosolic and nuclear effectors. Phosphorylates AKT1, AR, MCF2, WASL and WWOX. Implicated in trafficking and clathrin-mediated endocytosis through binding to epidermal growth factor receptor (EGFR) and clathrin. Binds to both poly- and mono-ubiquitin and regulates ligand-induced degradation of EGFR,

LOCALIZAÇÃO

Cell membraneNucleusEndosomeCell junction, adherens junctionCytoplasmic vesicle membraneCytoplasmic vesicle, clathrin-coated vesicleMembrane, clathrin-coated pitCytoplasm, perinuclear regionCytoplasm, cytosol

VIAS BIOLÓGICAS (1)
Signaling by LTK
VIAS REACTOME (1)
EXPRESSÃO TECIDUAL(Ubíquo)
Cerebelo
134.9 TPM
Cérebro - Hemisfério cerebelar
122.9 TPM
Córtex cerebral
112.4 TPM
Pituitária
112.0 TPM
Brain Frontal Cortex BA9
103.8 TPM
OUTRAS DOENÇAS (1)
infantile-onset mesial temporal lobe epilepsy with severe cognitive regression
HGNC:19297UniProt:Q07912
SCN8ASodium channel protein type 8 subunit alphaCandidate gene tested inAltamente restrito
FUNÇÃO

Pore-forming subunit of a voltage-gated sodium channel complex assuming opened or closed conformations in response to the voltage difference across membranes and through which sodium ions selectively pass along their electrochemical gradient (PubMed:24874546, PubMed:25239001, PubMed:25725044, PubMed:26900580, PubMed:29726066, PubMed:33245860, PubMed:36696443, PubMed:36823201). Contributes to neuronal excitability by regulating action potential threshold and propagation (PubMed:24874546, PubMed:2

LOCALIZAÇÃO

Cell membraneCell projection, axonCytoplasmic vesicleCell projection, podosome

VIAS BIOLÓGICAS (2)
Interaction between L1 and AnkyrinsPhase 0 - rapid depolarisation
MECANISMO DE DOENÇA

Cognitive impairment with or without cerebellar ataxia

A disorder characterized by markedly delayed cognitive and motor development, attention deficit disorder, and cerebellar ataxia. Features include bilateral esophoria, strabismatic amblyopia, unsustained gaze evoked nystagmus on horizontal gaze, ataxic gait, dysmetria in the upper limbs and dysarthria, with normal strength, tone, and reflexes.

EXPRESSÃO TECIDUAL(Tecido-específico)
Cerebelo
28.2 TPM
Cérebro - Hemisfério cerebelar
26.4 TPM
Brain Frontal Cortex BA9
17.9 TPM
Córtex cerebral
14.8 TPM
Pituitária
10.9 TPM
OUTRAS DOENÇAS (9)
seizures, benign familial infantile, 5developmental and epileptic encephalopathy, 13myoclonus, familial, 2cognitive impairment with or without cerebellar ataxia
HGNC:10596UniProt:Q9UQD0
CPLX1Complexin-1Candidate gene tested inModerado
FUNÇÃO

Positively regulates a late step in exocytosis of various cytoplasmic vesicles, such as synaptic vesicles and other secretory vesicles (PubMed:21785414). Organizes the SNAREs into a cross-linked zigzag topology that, when interposed between the vesicle and plasma membranes, is incompatible with fusion, thereby preventing SNAREs from releasing neurotransmitters until an action potential arrives at the synapse (PubMed:21785414). Also involved in glucose-induced secretion of insulin by pancreatic b

LOCALIZAÇÃO

Cytoplasm, cytosolPerikaryonPresynapse

VIAS BIOLÓGICAS (6)
Serotonin Neurotransmitter Release CycleGABA synthesis, release, reuptake and degradationGlutamate Neurotransmitter Release CycleNorepinephrine Neurotransmitter Release CycleAcetylcholine Neurotransmitter Release Cycle
MECANISMO DE DOENÇA

Developmental and epileptic encephalopathy 63

A form of epileptic encephalopathy, a heterogeneous group of severe early-onset epilepsies characterized by refractory seizures, neurodevelopmental impairment, and poor prognosis. Development is normal prior to seizure onset, after which cognitive and motor delays become apparent. DEE63 is an autosomal recessive disease with onset in infancy.

OUTRAS DOENÇAS (3)
developmental and epileptic encephalopathy, 63familial infantile myoclonic epilepsyWolf-Hirschhorn syndrome
HGNC:2309UniProt:O14810
HACE1E3 ubiquitin-protein ligase HACE1Disease-causing germline mutation(s) inTolerante
FUNÇÃO

E3 ubiquitin-protein ligase involved in Golgi membrane fusion and regulation of small GTPases (PubMed:15254018, PubMed:21988917, PubMed:22036506, PubMed:37537642, PubMed:38332367). Acts as a regulator of Golgi membrane dynamics during the cell cycle: recruited to Golgi membrane by Rab proteins and regulates postmitotic Golgi membrane fusion (PubMed:21988917). Acts by mediating ubiquitination during mitotic Golgi disassembly, ubiquitination serving as a signal for Golgi reassembly later, after ce

LOCALIZAÇÃO

Golgi apparatus, Golgi stack membraneCytoplasmEndoplasmic reticulum

VIAS BIOLÓGICAS (1)
Antigen processing: Ubiquitination & Proteasome degradation
EXPRESSÃO TECIDUAL(Ubíquo)
Cérebro - Hemisfério cerebelar
24.8 TPM
Cerebelo
23.5 TPM
Cervix Ectocervix
16.4 TPM
Nervo tibial
15.5 TPM
Cervix Endocervix
14.8 TPM
INTERAÇÕES PROTEICAS (3)
OUTRAS DOENÇAS (2)
spastic paraplegia-severe developmental delay-epilepsy syndromeneuroblastoma
HGNC:21033UniProt:Q8IYU2
BRAT1Integrator complex assembly factor BRAT1Disease-causing germline mutation(s) inTolerante
FUNÇÃO

Component of a multiprotein complex required for the assembly of the RNA endonuclease module of the integrator complex (PubMed:39032489, PubMed:39032490). Associates with INTS9 and INTS11 in the cytoplasm and blocks the active site of INTS11 to inhibit the endonuclease activity of INTS11 before formation of the full integrator complex (PubMed:39032489, PubMed:39032490). Following dissociation of WDR73 of the complex, BRAT1 facilitates the nuclear import of the INTS9-INTS11 heterodimer (PubMed:39

LOCALIZAÇÃO

NucleusCytoplasm

MECANISMO DE DOENÇA

Rigidity and multifocal seizure syndrome, lethal neonatal

A lethal, neonatal, neurologic disorder characterized by episodic jerking that is apparent in utero, lack of psychomotor development, axial and limb rigidity, frequent multifocal seizures, and dysautonomia. At birth, affected individuals have small heads, overlapping cranial sutures, small or absent fontanels, and depressed frontal bones. Infants show poorly responsive focal jerks of the tongue, face and arms in a nearly continuous sequence throughout life.

INTERAÇÕES PROTEICAS (2)
OUTRAS DOENÇAS (2)
neurodevelopmental disorder with cerebellar atrophy and with or without seizuresneonatal-onset encephalopathy with rigidity and seizures
HGNC:21701UniProt:Q6PJG6
CLN8Protein CLN8Disease-causing germline mutation(s) inTolerante
FUNÇÃO

Could play a role in cell proliferation during neuronal differentiation and in protection against cell death

LOCALIZAÇÃO

Endoplasmic reticulum membraneEndoplasmic reticulum-Golgi intermediate compartment membraneEndoplasmic reticulum

MECANISMO DE DOENÇA

Ceroid lipofuscinosis, neuronal, 8

A form of neuronal ceroid lipofuscinosis with onset in childhood. Neuronal ceroid lipofuscinoses are progressive neurodegenerative, lysosomal storage diseases characterized by intracellular accumulation of autofluorescent liposomal material, and clinically by seizures, dementia, visual loss, and/or cerebral atrophy. The lipopigment patterns observed most often in neuronal ceroid lipofuscinosis type 8 comprise mixed combinations of granular, curvilinear, and fingerprint profiles.

OUTRAS DOENÇAS (2)
neuronal ceroid lipofuscinosis 8neuronal ceroid lipofuscinosis 8 northern epilepsy variant
HGNC:2079UniProt:Q9UBY8
DOCK7Dedicator of cytokinesis protein 7Disease-causing germline mutation(s) inRestrito
FUNÇÃO

Functions as a guanine nucleotide exchange factor (GEF), which activates Rac1 and Rac3 Rho small GTPases by exchanging bound GDP for free GTP. Does not have a GEF activity for CDC42. Required for STMN1 'Ser-15' phosphorylation during axon formation and consequently for neuronal polarization (PubMed:16982419). As part of the DISP complex, may regulate the association of septins with actin and thereby regulate the actin cytoskeleton (PubMed:29467281). Has a role in pigmentation (By similarity). In

LOCALIZAÇÃO

Cell projection, axon

VIAS BIOLÓGICAS (4)
MET activates RAP1 and RAC1Factors involved in megakaryocyte development and platelet productionRAC1 GTPase cycleCDC42 GTPase cycle
MECANISMO DE DOENÇA

Developmental and epileptic encephalopathy 23

A severe disease characterized by early-onset intractable epilepsy, dysmorphic features, intellectual disability, and cortical blindness. Brain imaging shows an abnormally marked pontobulbar sulcus with mild pontine hypoplasia, white matter abnormalities, and atrophy in the occipital lobe.

EXPRESSÃO TECIDUAL(Ubíquo)
Fibroblastos
17.6 TPM
Nervo tibial
13.6 TPM
Cervix Endocervix
11.4 TPM
Cervix Ectocervix
11.4 TPM
Ovário
11.0 TPM
OUTRAS DOENÇAS (1)
developmental and epileptic encephalopathy, 23
HGNC:19190UniProt:Q96N67
CDKL5Cyclin-dependent kinase-like 5Disease-causing germline mutation(s) inAltamente restrito
FUNÇÃO

Mediates phosphorylation of MECP2 (PubMed:15917271, PubMed:16935860). May regulate ciliogenesis (PubMed:29420175)

LOCALIZAÇÃO

NucleusCytoplasm, cytoskeleton, cilium basal bodyCytoplasm, cytoskeleton, microtubule organizing center, centrosome

OUTRAS DOENÇAS (5)
developmental and epileptic encephalopathy, 2X-linked retinoschisisCDKL5 disorderearly-infantile DEE
HGNC:11411UniProt:O76039
PCDH19Protocadherin-19Disease-causing germline mutation(s) inAltamente restrito
FUNÇÃO

Calcium-dependent cell-adhesion protein

LOCALIZAÇÃO

Cell membrane

VIAS BIOLÓGICAS (1)
Formation of the nephric duct
MECANISMO DE DOENÇA

Developmental and epileptic encephalopathy 9

A condition characterized by seizure with onset in infancy or early childhood, cognitive impairment, and delayed development of variable severity in some patients. Additional features include autistic signs and psychosis. The disorder is sex-limited, with the phenotype being restricted to females.

EXPRESSÃO TECIDUAL(Tecido-específico)
Brain Frontal Cortex BA9
5.9 TPM
Hipotálamo
4.6 TPM
Córtex cerebral
4.5 TPM
Brain Anterior cingulate cortex BA24
4.2 TPM
Hipocampo
3.4 TPM
OUTRAS DOENÇAS (2)
developmental and epileptic encephalopathy, 9obsolete Dravet syndrome
HGNC:14270UniProt:Q8TAB3
SYN1Synapsin-1Disease-causing germline mutation(s) inAltamente restrito
FUNÇÃO

Neuronal phosphoprotein that coats synaptic vesicles, and binds to the cytoskeleton. Acts as a regulator of synaptic vesicles trafficking, involved in the control of neurotransmitter release at the pre-synaptic terminal (PubMed:21441247, PubMed:23406870). Also involved in the regulation of axon outgrowth and synaptogenesis (By similarity). The complex formed with NOS1 and CAPON proteins is necessary for specific nitric-oxid functions at a presynaptic level (By similarity)

LOCALIZAÇÃO

SynapseGolgi apparatusPresynapseCytoplasmic vesicle, secretory vesicle, synaptic vesicle

VIAS BIOLÓGICAS (2)
Serotonin Neurotransmitter Release CycleDopamine Neurotransmitter Release Cycle
MECANISMO DE DOENÇA

Epilepsy, X-linked 1, with variable learning disabilities and behavior disorders

A neurologic disorder characterized by variable combinations of epilepsy, learning difficulties, macrocephaly, and aggressive behavior.

EXPRESSÃO TECIDUAL(Ubíquo)
Brain Frontal Cortex BA9
295.2 TPM
Córtex cerebral
294.1 TPM
Cerebelo
243.5 TPM
Cérebro - Hemisfério cerebelar
219.2 TPM
Brain Anterior cingulate cortex BA24
208.1 TPM
OUTRAS DOENÇAS (2)
intellectual disability, X-linked 50epilepsy, X-linked 1, with variable learning disabilities and behavior disorders
HGNC:11494UniProt:P17600
GABRA3Gamma-aminobutyric acid receptor subunit alpha-3Disease-causing germline mutation(s) inRestrito
FUNÇÃO

Alpha subunit of the heteropentameric ligand-gated chloride channel gated by gamma-aminobutyric acid (GABA), a major inhibitory neurotransmitter in the brain (PubMed:16412217, PubMed:29053855). GABA-gated chloride channels, also named GABA(A) receptors (GABAAR), consist of five subunits arranged around a central pore and contain GABA active binding site(s) located at the alpha and beta subunit interface(s) (By similarity). When activated by GABA, GABAARs selectively allow the flow of chloride an

LOCALIZAÇÃO

Postsynaptic cell membraneCell membrane

VIAS BIOLÓGICAS (1)
GABA receptor activation
MECANISMO DE DOENÇA

Epilepsy, X-linked 2, with or without impaired intellectual development and dysmorphic features

A neurologic disorder characterized by variable combinations of epileptic seizure, and a varying degree of intellectual disability and developmental delay. Some patients have dysmorphic facial features or mild skeletal anomalies. In general, males are more severely affected than females, although there is evidence for incomplete penetrance in both sexes.

VIAS REACTOME (1)
EXPRESSÃO TECIDUAL(Tecido-específico)
Brain Frontal Cortex BA9
20.7 TPM
Brain Anterior cingulate cortex BA24
13.6 TPM
Hipotálamo
13.3 TPM
Córtex cerebral
12.6 TPM
Brain Nucleus accumbens basal ganglia
6.9 TPM
OUTRAS DOENÇAS (2)
epilepsy, X-linked 2, with or without impaired intellectual development and dysmorphic featuresthyrotoxic periodic paralysis
HGNC:4077UniProt:P34903
RNF13E3 ubiquitin-protein ligase RNF13Disease-causing germline mutation(s) inTolerante
FUNÇÃO

E3 ubiquitin-protein ligase that regulates cell proliferation (PubMed:18794910, PubMed:23378536, PubMed:30595371). Involved in apoptosis regulation (PubMed:23378536, PubMed:30595371). Mediates ER stress-induced activation of JNK signaling pathway and apoptosis by promoting ERN1 activation and splicing of XBP1 mRNA (PubMed:23378536, PubMed:30595371). Also involved in protein trafficking and localization (PubMed:24387786)

LOCALIZAÇÃO

Endoplasmic reticulum membraneLate endosome membraneLysosome membraneNucleus inner membrane

VIAS BIOLÓGICAS (8)
DDX58/IFIH1-mediated induction of interferon-alpha/betaSARS-CoV-2 activates/modulates innate and adaptive immune responsesNegative regulators of DDX58/IFIH1 signalingTRAF3-dependent IRF activation pathwayOvarian tumor domain proteases
MECANISMO DE DOENÇA

Developmental and epileptic encephalopathy 73

A form of epileptic encephalopathy, a heterogeneous group of severe early-onset epilepsies characterized by refractory seizures, neurodevelopmental impairment, and poor prognosis. Development is normal prior to seizure onset, after which cognitive and motor delays become apparent. DEE73 is an autosomal dominant form with onset at birth.

EXPRESSÃO TECIDUAL(Ubíquo)
Brain Spinal cord cervical c-1
147.3 TPM
Nervo tibial
89.4 TPM
Pulmão
57.9 TPM
Substância negra
51.3 TPM
Tecido adiposo
50.8 TPM
OUTRAS DOENÇAS (1)
developmental and epileptic encephalopathy, 73
HGNC:10057UniProt:O43567
MECP2Methyl-CpG-binding protein 2Disease-causing germline mutation(s) inAltamente restrito
FUNÇÃO

Chromosomal protein that binds to methylated DNA. It can bind specifically to a single methyl-CpG pair. It is not influenced by sequences flanking the methyl-CpGs. Mediates transcriptional repression through interaction with histone deacetylase and the corepressor SIN3A. Binds both 5-methylcytosine (5mC) and 5-hydroxymethylcytosine (5hmC)-containing DNA, with a preference for 5-methylcytosine (5mC)

LOCALIZAÇÃO

Nucleus

VIAS BIOLÓGICAS (7)
MECP2 regulates transcription of neuronal ligandsRegulation of MECP2 expression and activityMECP2 regulates neuronal receptors and channelsMECP2 regulates transcription factorsTranscriptional Regulation by MECP2
MECANISMO DE DOENÇA

Angelman syndrome

A neurodevelopmental disorder characterized by severe motor and intellectual retardation, ataxia, frequent jerky limb movements and flapping of the arms and hands, hypotonia, seizures, absence of speech, frequent smiling and episodes of paroxysmal laughter, open-mouthed expression revealing the tongue.

EXPRESSÃO TECIDUAL(Ubíquo)
Cérebro - Hemisfério cerebelar
38.8 TPM
Cerebelo
34.5 TPM
Útero
28.9 TPM
Artéria tibial
28.1 TPM
Fallopian Tube
27.9 TPM
OUTRAS DOENÇAS (8)
syndromic X-linked intellectual disability Lubs typeRett syndromeX-linked intellectual disability-psychosis-macroorchidism syndromesevere neonatal-onset encephalopathy with microcephaly
HGNC:6990UniProt:P51608
OTUD6BDeubiquitinase OTUD6BDisease-causing germline mutation(s) inTolerante
FUNÇÃO

Deubiquitinating enzyme that may play a role in the ubiquitin-dependent regulation of protein synthesis, downstream of mTORC1 (PubMed:21267069, PubMed:27864334). May associate with the protein synthesis initiation complex and modify its ubiquitination to repress translation (PubMed:27864334). May also repress DNA synthesis and modify different cellular targets thereby regulating cell growth and proliferation (PubMed:27864334). May also play a role in proteasome assembly and function (PubMed:2834

LOCALIZAÇÃO

MECANISMO DE DOENÇA

Intellectual developmental disorder with dysmorphic facies, seizures, and distal limb anomalies

An autosomal recessive severe multisystem disorder characterized by poor overall growth, developmental delay, early-onset seizures, intellectual disability, and dysmorphic features. Additional features include microcephaly, absent speech, hypotonia, feeding difficulties, structural brain abnormalities, congenital malformations including congenital heart disease, and musculoskeletal features.

EXPRESSÃO TECIDUAL(Ubíquo)
Linfócitos
21.9 TPM
Nervo tibial
15.1 TPM
Útero
13.0 TPM
Cervix Ectocervix
12.6 TPM
Ovário
12.0 TPM
INTERAÇÕES PROTEICAS (2)
OUTRAS DOENÇAS (1)
intellectual developmental disorder with dysmorphic facies, seizures, and distal limb anomalies
HGNC:24281UniProt:Q8N6M0
ARHGEF9Rho guanine nucleotide exchange factor 9Disease-causing germline mutation(s) inAltamente restrito
FUNÇÃO

Acts as a guanine nucleotide exchange factor (GEF) for CDC42. Promotes formation of GPHN clusters (By similarity)

LOCALIZAÇÃO

CytoplasmPostsynaptic density

VIAS BIOLÓGICAS (5)
G alpha (12/13) signalling eventsNRAGE signals death through JNKGABA receptor activationRHOQ GTPase cycleCDC42 GTPase cycle
MECANISMO DE DOENÇA

Developmental and epileptic encephalopathy 8

A disorder characterized by hyperekplexia and early infantile epileptic encephalopathy. Neurologic features include exaggerated startle response, seizures, impaired psychomotor development, and intellectual disability. Seizures can be provoked by tactile stimulation or extreme emotion.

OUTRAS DOENÇAS (1)
developmental and epileptic encephalopathy, 8
HGNC:14561UniProt:O43307
STRADASTE20-related kinase adapter protein alphaDisease-causing germline mutation(s) inTolerante
FUNÇÃO

Pseudokinase which, in complex with CAB39/MO25 (CAB39/MO25alpha or CAB39L/MO25beta), binds to and activates STK11/LKB1. Adopts a closed conformation typical of active protein kinases and binds STK11/LKB1 as a pseudosubstrate, promoting conformational change of STK11/LKB1 in an active conformation

LOCALIZAÇÃO

NucleusCytoplasm

VIAS BIOLÓGICAS (1)
Energy dependent regulation of mTOR by LKB1-AMPK
EXPRESSÃO TECIDUAL(Ubíquo)
Testículo
51.0 TPM
Cerebelo
36.5 TPM
Cérebro - Hemisfério cerebelar
35.4 TPM
Linfócitos
30.9 TPM
Nervo tibial
30.0 TPM
OUTRAS DOENÇAS (1)
polyhydramnios, megalencephaly, and symptomatic epilepsy
HGNC:30172UniProt:Q7RTN6
TBC1D24TBC1 domain family member 24Disease-causing germline mutation(s) inTolerante
FUNÇÃO

May act as a GTPase-activating protein for Rab family protein(s) (PubMed:20727515, PubMed:20797691). Involved in neuronal projections development, probably through a negative modulation of ARF6 function (PubMed:20727515). Involved in the regulation of synaptic vesicle trafficking (PubMed:31257402)

LOCALIZAÇÃO

Cell membraneCytoplasmCytoplasmic vesicle membranePresynapse

VIAS BIOLÓGICAS (1)
TBC/RABGAPs
MECANISMO DE DOENÇA

Familial infantile myoclonic epilepsy

A subtype of idiopathic epilepsy starting in early infancy and manifesting as myoclonic seizures, febrile convulsions, and tonic-clonic seizures.

VIAS REACTOME (1)
EXPRESSÃO TECIDUAL(Ubíquo)
Cerebelo
27.8 TPM
Cérebro - Hemisfério cerebelar
26.6 TPM
Brain Frontal Cortex BA9
11.4 TPM
Córtex cerebral
11.2 TPM
Pituitária
9.4 TPM
INTERAÇÕES PROTEICAS (2)
OUTRAS DOENÇAS (11)
familial infantile myoclonic epilepsyrolandic epilepsy-paroxysmal exercise-induced dystonia-writer's cramp syndromeautosomal dominant nonsyndromic hearing loss 65autosomal recessive nonsyndromic hearing loss 86
HGNC:29203UniProt:Q9ULP9
PUM1Pumilio homolog 1Disease-causing germline mutation(s) inAltamente restrito
FUNÇÃO

Sequence-specific RNA-binding protein that acts as a post-transcriptional repressor by binding the 3'-UTR of mRNA targets. Binds to an RNA consensus sequence, the Pumilio Response Element (PRE), 5'-UGUANAUA-3', that is related to the Nanos Response Element (NRE) (PubMed:18328718, PubMed:21397187, PubMed:21572425, PubMed:21653694). Mediates post-transcriptional repression of transcripts via different mechanisms: acts via direct recruitment of the CCR4-POP2-NOT deadenylase leading to translational

LOCALIZAÇÃO

CytoplasmCytoplasm, P-bodyCytoplasmic granule

VIAS BIOLÓGICAS (1)
Golgi Associated Vesicle Biogenesis
MECANISMO DE DOENÇA

Neurodevelopmental disorder with motor abnormalities, seizures, and facial dysmorphism

An autosomal dominant disorder characterized by global developmental delay, impaired intellectual development, early-onset seizures, poor overall growth, delayed walking, hypotonia and/or ataxia, and facial dysmorphism. Some patients have hypoplasia of the corpus callosum and cerebral atrophy.

EXPRESSÃO TECIDUAL(Ubíquo)
Útero
56.0 TPM
Ovário
54.0 TPM
Nervo tibial
52.9 TPM
Artéria tibial
52.6 TPM
Cérebro - Hemisfério cerebelar
51.0 TPM
OUTRAS DOENÇAS (2)
neurodevelopmental disorder with motor abnormalities, seizures, and facial dysmorphismspinocerebellar ataxia 47
HGNC:14957UniProt:Q14671
ZEB2Zinc finger E-box-binding homeobox 2Disease-causing germline mutation(s) inAltamente restrito
FUNÇÃO

Transcriptional inhibitor that binds to DNA sequence 5'-CACCT-3' in different promoters (PubMed:16061479, PubMed:20516212). Represses transcription of E-cadherin (PubMed:16061479). Represses expression of MEOX2 (PubMed:20516212)

LOCALIZAÇÃO

NucleusChromosome

VIAS BIOLÓGICAS (5)
Regulation of CDH11 gene transcriptionPositive Regulation of CDH1 Gene TranscriptionNegative Regulation of CDH1 Gene TranscriptionFormation of the posterior neural plateFormation of the anterior neural plate
MECANISMO DE DOENÇA

Mowat-Wilson syndrome

A complex developmental disorder characterized by intellectual disability, delayed motor development, epilepsy, microcephaly and a wide spectrum of clinically heterogeneous features suggestive of neurocristopathies at the cephalic, cardiac, and vagal levels. Affected patients show an easily recognizable facial appearance with deep set eyes and hypertelorism, medially divergent, broad eyebrows, prominent columella, pointed chin and uplifted, notched ear lobes. Some patients manifest Hirschsprung disease.

EXPRESSÃO TECIDUAL(Ubíquo)
Brain Spinal cord cervical c-1
67.9 TPM
Nervo tibial
47.6 TPM
Artéria tibial
33.1 TPM
Tecido adiposo
31.9 TPM
Substância negra
30.5 TPM
OUTRAS DOENÇAS (4)
Mowat-Wilson syndromeMowat-Wilson syndrome due to a ZEB2 point mutationlarge congenital melanocytic nevusMowat-Wilson syndrome due to monosomy 2q22
HGNC:14881UniProt:O60315
ATP6AP2Renin receptorDisease-causing germline mutation(s) inAltamente restrito
FUNÇÃO

Multifunctional protein which functions as a renin, prorenin cellular receptor and is involved in the assembly of the lysosomal proton-transporting V-type ATPase (V-ATPase) and the acidification of the endo-lysosomal system (PubMed:12045255, PubMed:29127204, PubMed:30374053, PubMed:32276428). May mediate renin-dependent cellular responses by activating ERK1 and ERK2 (PubMed:12045255). By increasing the catalytic efficiency of renin in AGT/angiotensinogen conversion to angiotensin I, may also pla

LOCALIZAÇÃO

Endoplasmic reticulum membraneLysosome membraneCytoplasmic vesicle, autophagosome membraneCell projection, dendritic spine membraneCell projection, axonEndosome membraneCytoplasmic vesicle, clathrin-coated vesicle membraneCytoplasmic vesicle, secretory vesicle, synaptic vesicle membrane

VIAS BIOLÓGICAS (2)
Metabolism of Angiotensinogen to AngiotensinsNeutrophil degranulation
MECANISMO DE DOENÇA

Intellectual developmental disorder, X-linked, syndromic, Hedera type

A disorder characterized by significantly below average general intellectual functioning associated with impairments in adaptive behavior and manifested during the developmental period. MRXSH patients manifest mild to moderate intellectual disability associated with epilepsy, delays in motor milestones and speech acquisition in infancy.

OUTRAS DOENÇAS (3)
syndromic X-linked intellectual disability Hedera typeX-linked parkinsonism-spasticity syndromecongenital disorder of glycosylation, type IIr
HGNC:18305UniProt:O75787
RUBCNRun domain Beclin-1-interacting and cysteine-rich domain-containing proteinDisease-causing germline mutation(s) inTolerante
FUNÇÃO

Inhibits PIK3C3 activity; under basal conditions negatively regulates PI3K complex II (PI3KC3-C2) function in autophagy. Negatively regulates endosome maturation and degradative endocytic trafficking and impairs autophagosome maturation process. Can sequester UVRAG from association with a class C Vps complex (possibly the HOPS complex) and negatively regulates Rab7 activation (PubMed:20974968, PubMed:21062745) Involved in regulation of pathogen-specific host defense of activated macrophages. Fol

LOCALIZAÇÃO

Late endosomeLysosomeEarly endosome

MECANISMO DE DOENÇA

Spinocerebellar ataxia, autosomal recessive, 15

A form of spinocerebellar ataxia, a clinically and genetically heterogeneous group of cerebellar disorders. Patients show progressive incoordination of gait and often poor coordination of hands, speech and eye movements, due to degeneration of the cerebellum with variable involvement of the brainstem and spinal cord. SCAR15 patients manifest cerebellar ataxia in early childhood and delayed motor development with delayed walking. Additional features include dysarthria, upper limb involvement, abnormal eye movements, and hyporeflexia.

EXPRESSÃO TECIDUAL(Ubíquo)
Linfócitos
38.4 TPM
Cérebro - Hemisfério cerebelar
34.0 TPM
Cerebelo
30.9 TPM
Testículo
27.1 TPM
Baço
26.4 TPM
OUTRAS DOENÇAS (1)
autosomal recessive spinocerebellar ataxia 15
HGNC:28991UniProt:Q92622
WWOXWW domain-containing oxidoreductaseDisease-causing germline mutation(s) inTolerante
FUNÇÃO

Putative oxidoreductase. Acts as a tumor suppressor and plays a role in apoptosis. Required for normal bone development (By similarity). May function synergistically with p53/TP53 to control genotoxic stress-induced cell death. Plays a role in TGFB1 signaling and TGFB1-mediated cell death. May also play a role in tumor necrosis factor (TNF)-mediated cell death. Inhibits Wnt signaling, probably by sequestering DVL2 in the cytoplasm

LOCALIZAÇÃO

CytoplasmNucleusMitochondrionGolgi apparatusLysosome

VIAS BIOLÓGICAS (3)
Nuclear signaling by ERBB4Activation of the TFAP2 (AP-2) family of transcription factorsNegative regulation of activity of TFAP2 (AP-2) family transcription factors
EXPRESSÃO TECIDUAL(Ubíquo)
Tireoide
13.8 TPM
Cérebro - Hemisfério cerebelar
12.1 TPM
Cerebelo
11.2 TPM
Brain Spinal cord cervical c-1
10.5 TPM
Nervo tibial
8.2 TPM
OUTRAS DOENÇAS (5)
autosomal recessive spinocerebellar ataxia 12esophageal cancerdevelopmental and epileptic encephalopathy, 28esophageal squamous cell carcinoma
HGNC:12799UniProt:Q9NZC7
NACC1Nucleus accumbens-associated protein 1Disease-causing germline mutation(s) inAltamente restrito
FUNÇÃO

Functions as a transcriptional repressor. Seems to function as a transcriptional corepressor in neuronal cells through recruitment of HDAC3 and HDAC4. Contributes to tumor progression, and tumor cell proliferation and survival. This may be mediated at least in part through repressing transcriptional activity of GADD45GIP1. Required for recruiting the proteasome from the nucleus to the cytoplasm and dendritic spines

LOCALIZAÇÃO

NucleusCytoplasm

MECANISMO DE DOENÇA

Neurodevelopmental disorder with epilepsy, cataracts, feeding difficulties, and delayed brain myelination

A neurodevelopmental disorder characterized by microcephaly, profound developmental delay, intellectual disability, cataracts, severe epilepsy including infantile spasms, irritability, failure to thrive, and stereotypic hand movements. Brain imaging reveals delayed myelination and cerebral atrophy.

EXPRESSÃO TECIDUAL(Ubíquo)
Fibroblastos
65.0 TPM
Linfócitos
61.3 TPM
Brain Frontal Cortex BA9
41.6 TPM
Cérebro - Hemisfério cerebelar
40.6 TPM
Cerebelo
38.3 TPM
OUTRAS DOENÇAS (1)
neurodevelopmental disorder with epilepsy, cataracts, feeding difficulties, and delayed brain myelination
HGNC:20967UniProt:Q96RE7

Variantes genéticas (ClinVar)

888 variantes patogênicas registradas no ClinVar.

🧬 TDP2: NM_016614.3(TDP2):c.591del (p.Pro198fs) ()
🧬 TDP2: NM_016614.3(TDP2):c.-17G>T ()
🧬 TDP2: NM_016614.3(TDP2):c.808-23G>C ()
🧬 TDP2: GRCh37/hg19 6p22.3-22.2(chr6:21704602-26187420)x1 ()
🧬 TDP2: NM_016614.3(TDP2):c.580_581del (p.Gln194fs) ()
Ver todas no ClinVar

Vias biológicas (Reactome)

51 vias biológicas associadas aos genes desta condição.

Nonhomologous End-Joining (NHEJ) Signaling by LTK Interaction between L1 and Ankyrins Phase 0 - rapid depolarisation Serotonin Neurotransmitter Release Cycle Norepinephrine Neurotransmitter Release Cycle Glutamate Neurotransmitter Release Cycle Dopamine Neurotransmitter Release Cycle Acetylcholine Neurotransmitter Release Cycle GABA synthesis, release, reuptake and degradation Antigen processing: Ubiquitination & Proteasome degradation MET activates RAP1 and RAC1 CDC42 GTPase cycle RAC1 GTPase cycle Factors involved in megakaryocyte development and platelet production Transcriptional Regulation by MECP2 Loss of function of MECP2 in Rett syndrome Regulation of MECP2 expression and activity Formation of the nephric duct Sensory processing of sound by inner hair cells of the cochlea GABA receptor activation RNF135 RNF130 RNF138 RNF139 RNF135,TRIM25,TRIM4 Loss of MECP2 binding ability to 5hmC-DNA Loss of phosphorylation of MECP2 at T308 Loss of MECP2 binding ability to the NCoR/SMRT complex Loss of MECP2 binding ability to 5mC-DNA MECP2 regulates neuronal receptors and channels MECP2 regulates transcription of neuronal ligands MECP2 regulates transcription factors MECP2 regulates transcription of genes involved in GABA signaling Nuclear events stimulated by ALK signaling in cancer NRAGE signals death through JNK G alpha (12/13) signalling events RHOQ GTPase cycle Energy dependent regulation of mTOR by LKB1-AMPK TBC/RABGAPs Golgi Associated Vesicle Biogenesis Regulation of CDH11 gene transcription Negative Regulation of CDH1 Gene Transcription Positive Regulation of CDH1 Gene Transcription Formation of the anterior neural plate Formation of the posterior neural plate Metabolism of Angiotensinogen to Angiotensins Neutrophil degranulation Nuclear signaling by ERBB4 Negative regulation of activity of TFAP2 (AP-2) family transcription factors Activation of the TFAP2 (AP-2) family of transcription factors

Diagnóstico

Os sinais que médicos procuram e os exames que confirmam

Carregando...

Tratamento e manejo

Remédios, cuidados de apoio e o que precisa acompanhar

Pipeline de tratamentos
Pipeline regulatório — de medicamentos já aprovados a drogas em pesquisa exploratória.
·Pré-clínico1
Medicamentos catalogadosEnsaios clínicos· 0 medicamentos · 1 ensaio
Carregando informações de tratamento...

Onde tratar no SUS

Hospitais de referência no Brasil e o protocolo oficial do SUS (PCDT)

🇧🇷 Atendimento SUS — Doença monogênica com epilepsia

🗺️

Selecione um estado ou use sua localização para ver resultados.

Dados de DATASUS/CNES, SBGM, ABNeuro e Ministério da Saúde. Sempre confirme a disponibilidade diretamente com o estabelecimento.

Pesquisa ativa

Ensaios clínicos abertos e novidades científicas recentes

🟢 Recrutando agora

1 pesquisa recrutando participantes. Converse com seu médico sobre a possibilidade de participar.

Outros ensaios clínicos

🧪 Está conduzindo uma pesquisa?
Divulgue para pacientes e familiares que acompanham esta doença.
Divulgar pesquisa →

Publicações mais relevantes

Timeline de publicações
0 papers (10 anos)
#1

Characterizing SCN1A -Related Disorders Using Real-World Data Across 681 Patient-Years.

medRxiv : the preprint server for health sciences2026 Mar 02

SCN1A -related disorders are the single most common monogenic cause of epilepsy and represent a major focus of precision medicine efforts. In conjunction with existing prospective studies, the analysis of real-world data obtained during routine clinical care can expand upon the scale and duration of available data and contribute to the development of meaningful outcomes for clinical trials. Here, we leveraged real-world data to delineate the longitudinal disease history of 100 individuals with SCN1A -related disorders using a systematic approach. We mapped a total of 671 unique clinical terms to a standardized framework in monthly increments across 681 patient-years, including 75 terms related to seizure types. Within this cohort, 89 individuals had presumed loss-of-function variants in SCN1A based on variant type and clinical diagnosis, including those with Dravet syndrome ( N = 79) and genetic epilepsy with febrile seizures plus ( N = 10). Ten individuals had a non-Dravet developmental and epileptic encephalopathy caused by gain-of-function variants in SCN1A . By annotating seizure type and frequency in monthly time-bins, we assessed seizure burden. A median of 17 changes in seizure frequency and ten terms referring to seizure type were identified per participant. Myoclonic seizures occurred with high frequency (median >5 daily), whereas hemiclonic, focal impaired consciousness, and bilateral tonic-clonic seizures occurred more rarely (median monthly). Retrospective analysis of developmental histories showed a range of cognitive abilities. Neurodevelopmental differences were observed in 83% (83/100) of individuals, of whom 83% (69/83) demonstrated delayed language skills. Motor coordination impairments, including gait disturbance, ataxia, hypotonia, and imbalance were annotated in 69% (69/100) of participants. EEG findings varied with age; most were reported as normal before nine months of age, after which the prevalence of abnormal interictal findings increased. Individuals with different clinical syndromes had unique medication landscapes, with 554 prescriptions of 37 unique therapies. Changes in treatment coincided with the diagnosis of an SCN1A -related disorder, with an increase in cannabidiol, clobazam, and fenfluramine and reduction in sodium channel-blocker use following genetic diagnosis. In summary, we reconstructed the longitudinal disease history of SCN1A -related disorders from electronic medical records using a standardized framework for the analysis of real-world clinical data. We refine existing natural history data of SCN1A -related disorders by providing a granular landscape of seizures, comorbidities, and treatment approaches over time.

#2

Mitochondrial Dysfunction in Monogenic Developmental and Epileptic Encephalopathies.

Pediatric neurology2026 Feb 13

Before diagnostic whole exome sequencing, monogenic/chromosomal developmental and epileptic encephalopathies (DEEs) were frequently misdiagnosed as mitochondrial disorders (MDs) with epilepsy, due to overlapping clinical and biochemical features. Assessing muscle functional assays in patients with a genetic diagnosis and epilepsy offers a unique opportunity to explore mitochondrial dysfunction in monogenic/chromosomal DEEs, in comparison to the mitochondrial dysfunction observed in genetically confirmed MDs. In this retrospective cohort study, clinical and biochemical data were extracted from patients suspected of MD with epilepsy who underwent muscle/fibroblast biopsy (2005-2015). Patients were classified into four groups based on the final diagnosis. Mitochondrial Disease Criteria scores were assigned. Statistical analyses were conducted using Fisher's exact, analysis of variance, and Kruskal-Wallis tests. Of 27 included participants, eleven (40.7%) had DEEs, four (14.8%) had genetically confirmed MDs, eight (29.6%) were suspected MD cases without genetic confirmation, and four (14.8%) had nonmitochondrial metabolic diseases. Mitochondrial dysfunction was common across all groups; 85% of participants met probable/definite Mitochondrial Disease Criteria, over 70% had elevated plasma lactate (>2.5 mmol/L), and 92% exhibited impaired adenosine triphosphate production. Surprisingly, moderate to severe complex dysfunction was observed in all groups except genetically confirmed MDs. Our findings indicate that mitochondrial dysfunction is prevalent in nonmitochondrial DEEs. Patients previously diagnosed with an MD based only on muscle/fibroblast biopsy may benefit from whole exome sequencing to identify genetic variants, for which targeted therapy may be available. Future research should explore whether treatment or prognosis of nonmitochondrial DEEs should be tailored to improve mitochondrial function.

#3

Research progress in SYNGAP1-related neurodevelopmental disorders: from pathogenesis to therapeutic strategies.

Frontiers in neurology2026

SYNGAP1-related neurodevelopmental disorder (SRD) is a monogenic inherited brain disorder caused by heterozygous loss-of-function mutations in the SYNGAP1 gene. The clinical presentation is complex, with core features including global developmental delay/intellectual disability, epilepsy, autism spectrum disorder, and various behavioral abnormalities. The SynGAP protein, encoded by the SYNGAP1 gene, is a key regulatory protein in the postsynaptic density of excitatory neurons. Through its GTPase-activating protein activity and structural scaffolding functions, it plays a central role in regulating the Ras/Rap signaling pathways, AMPA receptor trafficking, and maintaining the excitatory/inhibitory balance of neural networks. Haploinsufficiency of SynGAP leads to synaptic plasticity disruption and neural circuit imbalance, thereby triggering a series of neurophysiological and behavioral phenotypes. This article systematically reviews the molecular pathogenesis of SRDs, summarizes advances in treatment from conventional anti-seizure medications to emerging precision therapeutic strategies such as gene supplementation, antisense oligonucleotide-mediated splicing modulation, and translation-activating RNAs, and discusses current research challenges and future directions. Key concepts central to understanding SRDs include the critical developmental periods during which SynGAP exerts its primary influence on synaptic maturation, and cell-type specificity, referring to the differential expression and function of SynGAP in distinct neuronal populations (e.g., excitatory pyramidal neurons vs. parvalbumin-positive interneurons), which underlies circuit-level dysfunction. The aim is to provide a comprehensive perspective for an in-depth understanding of the disease and to support the development of effective therapies.

#4

International Clinical Evidence-based Guideline for Kleefstra Syndrome.

Genetics in medicine : official journal of the American College of Medical Genetics2026 Jan 20

Kleefstra syndrome (KLEFS1) is a rare monogenic neurodevelopmental disorder (mNDD) with multisystem involvement, caused by disruption of EHMT1 function, resulting in significant burden on affected individuals and their families. The current shortage of and globally scattered syndrome-specific knowledge has led to significant disparities in the access to and provision of evidence-based and individual-centered expert care. To address the challenges and improve outcomes for individuals with KLEFS1, an international KLEFS1 guideline consortium was formed consisting of 43 participants, both clinical experts and patient-representatives, from 15 different countries. The primary goal of the consortium was to develop a comprehensive and high-quality guideline for KLEFS1, aiming to enhance patient care, establish a uniform minimum international standard of care, and support decision-making. The current clinical guideline is evidence-based and includes 66 tailored recommendations to improve KLEFS1 care. The comprehensive methodological approach ensures broad consensus and supports effective implementation. Furthermore, this guideline serves as a valuable methodological model for guideline development in the context of rare disorders.

#5

Seizure outcomes after VNS therapy in children with drug-resistant epilepsy due to monogenic etiologies versus malformations of cortical development.

Journal of neurosurgery. Pediatrics2026 Jan 09

Vagus nerve stimulation (VNS) is an established adjunctive therapy for drug-resistant epilepsy (DRE). However, evidence regarding its efficacy in children with structural and nonstructural etiologies of epilepsy remains limited. Herein, the authors aimed to explore the effectiveness of VNS in patients with either etiology. In this retrospective single-center study, authors evaluated children (ages 2-18 years) with DRE due to nonlesional monogenic epilepsies (MEs) or malformations of cortical development (MCDs) who had undergone VNS device implantation between 2008 and 2024 and had ≥ 6 months of follow-up. Patients with tuberous sclerosis complex were excluded. Clinical, genetic, neuroimaging, VNS programming, and outcome data were extracted from medical records. The primary outcome was the responder rate, defined as > 50% seizure reduction from baseline at 6 months, 12 months, and the last follow-up, in the two groups. Of 336 VNS device recipients, 64 children with ME (n = 44) or MCD (n = 20) met the study inclusion criteria. The median follow-up was 3.5-4.0 years. The responder rate in the ME versus MCD group at 6 months, 1 year, and the last follow-up was 38.6% versus 42.1% (p = 0.77), 45.7% versus 44.4% (p = 0.46), and 47.6% versus 63.2% (p = 0.64), respectively. The SCN1A-related Dravet syndrome (SCN1A-DS) subgroup (n = 12) had a responder rate (50.0%) comparable to that of the non-SCN1A-DS ME group (43.7%) at the last follow-up. The frequency of status epilepticus decreased significantly in both groups (p = 0.03). VNS was well tolerated, with mild to moderate side effects reported in < 5% patients. No clinical variable, including age at seizure onset, epilepsy duration, or age at VNS device implantation predicted seizure outcomes. VNS therapy was noted to have a similar responder rate in children with DRE due to MEs or MCDs. Both groups experienced meaningful benefits, with a small proportion of patients experiencing mild side effects.

Publicações recentes

Ver todas no PubMed

📚 EuropePMCmostrando 198

2026

Characterizing SCN1A -Related Disorders Using Real-World Data Across 681 Patient-Years.

medRxiv : the preprint server for health sciences
2026

Mitochondrial Dysfunction in Monogenic Developmental and Epileptic Encephalopathies.

Pediatric neurology
2026

Research progress in SYNGAP1-related neurodevelopmental disorders: from pathogenesis to therapeutic strategies.

Frontiers in neurology
2026

Molecular Profiling of Polish Pediatric Patients with Epilepsy: A Single-Center Diagnostic Experience Using Next-Generation Sequencing.

Genes
2026

Neurocardiogenetics: Exploring the association of rare RYR2 variants with neuropsychiatric disorders in general and disease populations.

Journal of neurogenetics
2026

Genetic Risk Factors for Epilepsy: From Familial Studies to Gene Discoveries and Polygenic Risk Scores, Strides Toward Unlocking an Age-Old Question in Epilepsy.

Epilepsy currents
2026

AAV-mediated gene therapy in a SLC13A5 citrate transporter disorder model rescues epileptic and metabolic phenotypes.

The Journal of clinical investigation
2025

Endoplasmic reticulum protein retention and disturbed proteostasis is a common pathology for a subset of autism: evidence from mutations in GABAA receptors and GABA transporter 1.

Frontiers in molecular neuroscience
2026

International Clinical Evidence-based Guideline for Kleefstra Syndrome.

Genetics in medicine : official journal of the American College of Medical Genetics
2026

Seizure outcomes after VNS therapy in children with drug-resistant epilepsy due to monogenic etiologies versus malformations of cortical development.

Journal of neurosurgery. Pediatrics
2026

Altered Auditory Maturation in Fragile X Syndrome and Its Involvement in Audiogenic Seizure Susceptibility.

Autism research : official journal of the International Society for Autism Research
2025

Atypical GNAO1 variants in severe childhood speech disorders: clinical, genetic, and molecular insights.

Molecular autism
2025

Revealing Monogenic Diabetes: Clinical and Genetic Features of Pediatric MODY Cases in Türkiye: Single Center Experience.

Pediatric diabetes
2025

Precision medicine for sodium channelopathy-related autism and epilepsy.

Trends in molecular medicine
2026

Genetic Variants and Disease Mechanisms: Lessons from Monogenic Childhood Epilepsies.

Neuropediatrics
2026

Clinical and genetic landscape of epilepsies with absence seizures and single-gene etiology.

Epilepsia
2026

GRIN2A null variants confer a high risk for early-onset schizophrenia and other mental disorders and potentially enable precision therapy.

Molecular psychiatry
2026

The LMSz method - an automatable scalable approach to constructing gene-specific growth charts in rare disorders.

European journal of human genetics : EJHG
2026

Children With Pancreatic Hypoplasia Experience Poor Weight Gain and Labile Diabetes but Low Incidence of DKA.

The Journal of clinical endocrinology and metabolism
2026

Atenolol rescues premature mortality in genetic mouse models of sudden unexpected death in epilepsy.

Epilepsia
2026

Whole Exome Sequencing Based Diagnostics in Complex Childhood Epilepsy Syndromes-A Cohort Study on Clinical Utility.

Clinical genetics
2025

Epilepsy-Associated SCN2A-L1342P Mutation Drives Network Hyperexcitability and Widespread Transcriptomic Changes in Human Cortical Organoids.

bioRxiv : the preprint server for biology
2025

Neonatal diabetes mellitus is a significant feature of COXPD-24 caused by recessive NARS2 variants.

Diabetic medicine : a journal of the British Diabetic Association
2025

CSF IL-6 in children with neuroinflammatory conditions.

European journal of paediatric neurology : EJPN : official journal of the European Paediatric Neurology Society
2025

ELFN1 deficiency: The mechanistic basis and phenotypic spectrum of a neurodevelopmental disorder with epilepsy.

Genetics in medicine : official journal of the American College of Medical Genetics
2025

Emerging Insights into the Pathogenic Mechanisms of Dravet Syndrome.

Neurochemical research
2025

Increased Activity-Dependent Bulk Endocytosis in Huntington's Disease Results From Huntingtin Haploinsufficiency.

Journal of neurochemistry
2025

Genome-Wide Insights and Polygenic Risk Scores in Common Epilepsies: A Narrative Review.

American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics
2025

SCN9A should not be considered an epilepsy gene; Refuting a gene-disease association.

Epilepsia
2025

Bridging the gap: Canine in vitro models of the central nervous system as tools to study pathogenetic mechanisms in neurodegenerative disease and neuroinfectiology.

Veterinary pathology
2025

Precision therapies for genetic epilepsies in 2025: Promises and pitfalls.

Epilepsia open
2025

Convergent depression of activity-dependent bulk endocytosis in rodent models of autism spectrum disorder.

Molecular autism
2025

Mutations in the small nuclear RNA gene RNU2-2 cause a severe neurodevelopmental disorder with prominent epilepsy.

Nature genetics
2025

Genome-wide association study of idiopathic epilepsy in the Italian Spinone dog breed.

PloS one
2025

Rare disease gene association discovery in the 100,000 Genomes Project.

Nature
2025

State-of-the-art gene therapy in epilepsy.

Current opinion in neurology
2025

Roadmap to advance therapeutics for SYNGAP1-related disorder: a patient organization perspective from SynGAP Research Fund.

Therapeutic advances in rare disease
2025

Polygenic risk score to the rescue of monogenic diseases? The case of epilepsy.

EBioMedicine
2025

Childhood-onset focal epilepsy and acute para-infectious encephalopathy in a patient with biallelic QARS1 variants.

Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology
2024

Novel PNPLA8 variants associated with primary ovarian insufficiency, tremors, cerebellar ataxia and limb weakness: a case report and literature review.

Journal of neurology
2024

National survey on the prevalence of single-gene aetiologies for genetic developmental and epileptic encephalopathies in Italy.

Journal of medical genetics
2024

Human iPSC-derived microglia sense and dampen hyperexcitability of cortical neurons carrying the epilepsy-associated SCN2A-L1342P mutation.

The Journal of neuroscience : the official journal of the Society for Neuroscience
2025

A homozygous TARS2 variant is a novel cause of syndromic neonatal diabetes.

Diabetic medicine : a journal of the British Diabetic Association
2024

Investigating the effect of polygenic background on epilepsy phenotype in 'monogenic' families.

EBioMedicine
2024

Tremor-Dominant Movement Disorder in ANKRD11- Associated KBG Syndrome.

Tremor and other hyperkinetic movements (New York, N.Y.)
2024

Clinical Neurologic Features and Evaluation of PTEN Hamartoma Tumor Syndrome: A Systematic Review.

Neurology
2024

Discovery of a TRMT10A mutation in a case of atypical diabetes: Case report.

Diabetes &amp; metabolism
2024

Developmental and epileptic encephalopathies.

Nature reviews. Disease primers
2024

Preclinical studies of gene replacement therapy for CDKL5 deficiency disorder.

Molecular therapy : the journal of the American Society of Gene Therapy
2024

Enhanced hippocampal LTP but normal NMDA receptor and AMPA receptor function in a rat model of CDKL5 deficiency disorder.

Molecular autism
2024

The 2017 and 2022 ILAE epilepsy classification systems identify needs and opportunities in care: A paediatric hospital-based study.

Epilepsy &amp; behavior : E&amp;B
2024

Genome Sequencing for Diagnosing Rare Diseases.

The New England journal of medicine
2024

Neurological Diseases and Prevalence of Antineuronal Antibodies in Patients with Autoimmune Polyendocrine Syndrome Type 1 - A National Cohort Study.

Journal of clinical immunology
2024

Epilepsies with onset during the first year of life: A prospective study on syndromes, etiologies, and outcomes.

Epilepsia open
2024

Gene replacement therapies for inherited disorders of neurotransmission: Current progress in succinic semialdehyde dehydrogenase deficiency.

Journal of inherited metabolic disease
2024

G protein-coupled receptor (GPCR) gene variants and human genetic disease.

Critical reviews in clinical laboratory sciences
2024

Preimplantation genetic testing for monogenic disorders (PGT-M) offers an alternative strategy to prevent children from being born with hereditary neurological diseases or metabolic diseases dominated by nervous system phenotypes: a retrospective study.

Journal of assisted reproduction and genetics
2024

Cerebral visual impairment: genetic diagnoses and phenotypic associations.

Journal of medical genetics
2024

Genetic and phenotypic landscape of pediatric-onset epilepsy in 142 Indian families: Counseling and therapeutic implications.

Clinical genetics
2024

Genetic architecture of childhood speech disorder: a review.

Molecular psychiatry
2023

Next-generation sequencing testing in children with epilepsy reveals novel clinical, diagnostic and therapeutic implications.

Frontiers in genetics
2023

Rare disease gene association discovery from burden analysis of the 100,000 Genomes Project data.

medRxiv : the preprint server for health sciences
2024

FDA Patient-Focused Drug Development Guidances: Considerations for Trial Readiness in Rare Developmental and Epileptic Encephalopathies.

Neurology
2024

Distinctive In Vitro Phenotypes in iPSC-Derived Neurons From Patients With Gain- and Loss-of-Function SCN2A Developmental and Epileptic Encephalopathy.

The Journal of neuroscience : the official journal of the Society for Neuroscience
2024

Leveraging multiple approaches for the detection of pathogenic deep intronic variants in developmental and epileptic encephalopathies: A case report.

Epilepsia open
2023

Prospective evaluation of NGS-based sequencing in epilepsy patients: results of seven NASGE-associated diagnostic laboratories.

Frontiers in neurology
2024

The role of copy number variants in the genetic architecture of common familial epilepsies.

Epilepsia
2024

Pentanucleotide Repeat Insertions in RAI1 Cause Benign Adult Familial Myoclonic Epilepsy Type 8.

Movement disorders : official journal of the Movement Disorder Society
2024

De novo variants in RNF213 are associated with a clinical spectrum ranging from Leigh syndrome to early-onset stroke.

Genetics in medicine : official journal of the American College of Medical Genetics
2024

BK Channelopathies and KCNMA1-Linked Disease Models.

Annual review of physiology
2024

Electroclinical features and phenotypic differences in adenylosuccinate lyase deficiency: Long-term follow-up of seven patients from four families and appraisal of the literature.

Epilepsia open
2023

RNA therapeutics for epilepsy: An emerging modality for drug discovery.

Epilepsia
2023

Safe use of the ketogenic diet in an infant with microcephaly, epilepsy, and diabetes syndrome: a case report.

BMC pediatrics
2023

Recurrent Ischemic Strokes due to Monogenic COL4A1 Mutation: The First Case Report from Latin America.

Case reports in genetics
2023

Reversal of cell, circuit and seizure phenotypes in a mouse model of DNM1 epileptic encephalopathy.

Nature communications
2023

Familial Mesial Temporal Lobe Epilepsy: Clinical Spectrum and Genetic Evidence for a Polygenic Architecture.

Annals of neurology
2022

Diet in treatment of autism spectrum disorders.

Frontiers in neuroscience
2023

Recent advances in neurometabolic diseases: The genetic role in the modern era.

Epilepsy &amp; behavior : E&amp;B
2023

Strain-dependent effects on neurobehavioral and seizure phenotypes in Scn2aK1422E mice.

bioRxiv : the preprint server for biology
2023

Zebrafish as an Innovative Tool for Epilepsy Modeling: State of the Art and Potential Future Directions.

International journal of molecular sciences
2023

Exome Sequencing and Multigene Panel Testing in 1,411 Patients With Adult-Onset Neurologic Disorders.

Neurology. Genetics
2023

Implementation of Exome Sequencing in Clinical Practice for Neurological Disorders.

Genes
2023

Widespread genomic influences on phenotype in Dravet syndrome, a 'monogenic' condition.

Brain : a journal of neurology
2023

Case report: Neonatal diabetes mellitus caused by KCNJ11 mutation presenting with intracranial hemorrhage.

Frontiers in neurology
2023

Pediatric-Onset Epilepsy and Developmental Epileptic Encephalopathies Followed by Early-Onset Parkinsonism.

International journal of molecular sciences
2023

De Novo Variant in the KCNJ9 Gene as a Possible Cause of Neonatal Seizures.

Genes
2023

Neuropathy, Ataxia, and Retinitis Pigmentosa Syndrome.

Journal of clinical neuromuscular disease
2023

Genes4Epilepsy: An epilepsy gene resource.

Epilepsia
2023

Homozygous Missense Variant in the N-Terminal Region of ANK3 Gene Is Associated with Developmental Delay, Seizures, Speech Abnormality, and Aggressive Behavior.

Molecular syndromology
2023

Cytogenomic epileptology.

Molecular cytogenetics
2023

GRIN2A-related epilepsy and speech disorders: A comprehensive overview with a focus on the role of precision therapeutics.

Epilepsy research
2023

Transcriptomic analyses reveal neuronal specificity of Leigh syndrome associated genes.

Journal of inherited metabolic disease
2022

Estimating the Prevalence of De Novo Monogenic Neurodevelopmental Disorders from Large Cohort Studies.

Biomedicines
2022

Association of Vascular Risk Factors and Genetic Factors With Penetrance of Variants Causing Monogenic Stroke.

JAMA neurology
2022

A rigorous in silico genomic interrogation at 1p13.3 reveals 16 autosomal dominant candidate genes in syndromic neurodevelopmental disorders.

Frontiers in molecular neuroscience
2023

The phenotypic spectrum associated with loss-of-function variants in monogenic epilepsy genes in the general population.

European journal of human genetics : EJHG
2022

A systems medicine strategy to predict the efficacy of drugs for monogenic epilepsies.

Epilepsia
2022

SLC13A5 Deficiency Disorder: From Genetics to Gene Therapy.

Genes
2022

GABRG1 variant as a potential novel cause of epileptic encephalopathy, hypotonia, and global developmental delay.

American journal of medical genetics. Part A
2022

Expression of a Secretable, Cell-Penetrating CDKL5 Protein Enhances the Efficacy of Gene Therapy for CDKL5 Deficiency Disorder.

Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics
2022

Multi-Omic Investigations of a 17-19 Translocation Links MINK1 Disruption to Autism, Epilepsy and Osteoporosis.

International journal of molecular sciences
2022

Monogenic developmental and epileptic encephalopathies of infancy and childhood, a population cohort from Norway.

Frontiers in pediatrics
2022

Gene Therapy: Novel Approaches to Targeting Monogenic Epilepsies.

Frontiers in neurology
2022

Understanding Protein Protocadherin-19 (PCDH19) Syndrome: A Literature Review of the Pathophysiology.

Cureus
2022

Genomics in the presurgical epilepsy evaluation.

Epilepsy research
2022

Sulfonylurea for improving neurological features in neonatal diabetes: A systematic review and meta-analyses.

Pediatric diabetes
2022

Common risk variants for epilepsy are enriched in families previously targeted for rare monogenic variant discovery.

EBioMedicine
2022

SEMA6B variants cause intellectual disability and alter dendritic spine density and axon guidance.

Human molecular genetics
2022

Whole exome sequencing and co-expression analysis identify an SCN1A variant that modifies pathogenicity in a family with genetic epilepsy and febrile seizures plus.

Epilepsia
2022

Multiple Early-Life Seizures Alters Neonatal Communicative Behavior in Fmr1 Knockout Mice.

Developmental neuroscience
2022

Pathophysiological Heterogeneity of the BBSOA Neurodevelopmental Syndrome.

Cells
2022

'Channeling' therapeutic discovery for epileptic encephalopathy through iPSC technologies.

Trends in pharmacological sciences
2022

Efficacy of Ketogenic Diet for Infantile Spasms in Chinese Patients With or Without Monogenic Etiology.

Frontiers in pediatrics
2022

Reflex seizures in rare monogenic epilepsies.

Seizure
2022

Inhibition of MEK-ERK signaling reduces seizures in two mouse models of tuberous sclerosis complex.

Epilepsy research
2022

The EPIGENE network: A French initiative to harmonize and improve the nationwide diagnosis of monogenic epilepsies.

European journal of medical genetics
2022

Development and Validation of a Prediction Model for Early Diagnosis of SCN1A-Related Epilepsies.

Neurology
2022

Genetic diagnosis of basal ganglia disease in childhood.

Developmental medicine and child neurology
2021

Structural and Functional Aspects of the Neurodevelopmental Gene NR2F1: From Animal Models to Human Pathology.

Frontiers in molecular neuroscience
2022

De novo coding variants in the AGO1 gene cause a neurodevelopmental disorder with intellectual disability.

Journal of medical genetics
2021

Case Report: Lennox-Gastaut Epileptic Encephalopathy Responsive to Cannabidiol Treatment Associated With a Novel de novo Mosaic SHANK1 Variant.

Frontiers in genetics
2022

Identification and quantification of oligogenic loss-of-function disorders.

Genetics in medicine : official journal of the American College of Medical Genetics
2022

Novel treatments in epilepsy guided by genetic diagnosis.

British journal of clinical pharmacology
2021

100,000 Genomes Pilot on Rare-Disease Diagnosis in Health Care - Preliminary Report.

The New England journal of medicine
2021

Monogenic Epilepsies: Disease Mechanisms, Clinical Phenotypes, and Targeted Therapies.

Neurology
2021

Rett Syndrome Spectrum in Monogenic Developmental-Epileptic Encephalopathies and Epilepsies: A Review.

Genes
2021

CRISPRa-Mediated Upregulation of scn1laa During Early Development Causes Epileptiform Activity and dCas9-Associated Toxicity.

The CRISPR journal
2021

Dystonia as a prominent presenting feature in developmental and epileptic encephalopathies: A case series.

Parkinsonism &amp; related disorders
2021

Genotype-Phenotype Relations for the Atypical Parkinsonism Genes: MDSGene Systematic Review.

Movement disorders : official journal of the Movement Disorder Society
2021

Expanding the KIF4A-associated phenotype.

American journal of medical genetics. Part A
2021

Predictors of cognitive, behavioural and academic difficulties in NF1.

Journal of psychiatric research
2021

PPFIA4 mutation: A second hit in POLG related disease?

Epilepsy &amp; behavior reports
2021

TSPEAR variants are primarily associated with ectodermal dysplasia and tooth agenesis but not hearing loss: A novel cohort study.

American journal of medical genetics. Part A
2021

Retinoschisis and Norrie disease: a missing link.

BMC research notes
2021

Elp2 mutations perturb the epitranscriptome and lead to a complex neurodevelopmental phenotype.

Nature communications
2021

Integration of whole genome sequencing into a healthcare setting: high diagnostic rates across multiple clinical entities in 3219 rare disease patients.

Genome medicine
2021

AAV-Mediated Gene Therapy for Glycosphingolipid Biosynthesis Deficiencies.

Trends in molecular medicine
2021

Generation and characterization of human induced pluripotent stem cells (iPSCs) from three male and three female patients with CDKL5 Deficiency Disorder (CDD).

Stem cell research
2021

Etiologic distribution and clinical characteristics of pediatric diabetes in 276 children and adolescents with diabetes at a single academic center.

BMC pediatrics
2021

Genetic Factors Underlying Sudden Infant Death Syndrome.

The application of clinical genetics
2021

Expanding the phenotype, genotype and biochemical knowledge of ALG3-CDG.

Journal of inherited metabolic disease
2021

Genetic Dystonias: Update on Classification and New Genetic Discoveries.

Current neurology and neuroscience reports
2021

De novo TRIM8 variants impair its protein localization to nuclear bodies and cause developmental delay, epilepsy, and focal segmental glomerulosclerosis.

American journal of human genetics
2021

FBXO28 causes developmental and epileptic encephalopathy with profound intellectual disability.

Epilepsia
2020

Modelling genetic mosaicism of neurodevelopmental disorders in vivo by a Cre-amplifying fluorescent reporter.

Nature communications
2020

No association between SCN9A and monogenic human epilepsy disorders.

PLoS genetics
2020

Clinical and genetic characteristics and prenatal diagnosis of patients presented GDD/ID with rare monogenic causes.

Orphanet journal of rare diseases
2020

The off-label use of anakinra in pediatric systemic autoinflammatory diseases.

Therapeutic advances in musculoskeletal disease
2021

Epilepsy and neurobehavioral abnormalities in mice with a dominant-negative KCNB1 pathogenic variant.

Neurobiology of disease
2020

Monogenic variants in dystonia: an exome-wide sequencing study.

The Lancet. Neurology
2020

Prenatal diagnosis of Norrie disease after whole exome sequencing of an affected proband during an ongoing pregnancy: a case report.

BMC medical genetics
2020

Tuberous Sclerosis Complex as Disease Model for Investigating mTOR-Related Gliopathy During Epileptogenesis.

Frontiers in neurology
2020

Neurological disorder-associated genetic variants in individuals with psychogenic nonepileptic seizures.

Scientific reports
2020

Mutations of the Transcriptional Corepressor ZMYM2 Cause Syndromic Urinary Tract Malformations.

American journal of human genetics
2020

Early-onset epileptic encephalopathy with migrating focal seizures associated with a FARS2 homozygous nonsense variant.

Epileptic disorders : international epilepsy journal with videotape
2020

[Hereditary Parkinson’s disease as a new clinical manifestation of the damaged POLG gene].

Orvosi hetilap
2020

ExpansionHunter Denovo: a computational method for locating known and novel repeat expansions in short-read sequencing data.

Genome biology
2020

Bi-allelic GAD1 variants cause a neonatal onset syndromic developmental and epileptic encephalopathy.

Brain : a journal of neurology
2020

CACNA1H variants are not a cause of monogenic epilepsy.

Human mutation
2020

Ischemic Stroke in Young Adults.

Continuum (Minneapolis, Minn.)
2020

A deletion in Eml1 leads to bilateral subcortical heterotopia in the tish rat.

Neurobiology of disease
2020

A catalogue of new incidence estimates of monogenic neurodevelopmental disorders caused by de novo variants.

Brain : a journal of neurology
2020

Migraine With Aura as Early Disease Marker in Hereditary Dutch-Type Cerebral Amyloid Angiopathy.

Stroke
2020

Grandparental genotyping enhances exome variant interpretation.

American journal of medical genetics. Part A
2020

From Genetic Testing to Precision Medicine in Epilepsy.

Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics
2020

Chromatin remodeling dysfunction extends the etiological spectrum of schizophrenia: a case report.

BMC medical genetics
2020

Structural Noninfectious Manifestations of the Central Nervous System in Common Variable Immunodeficiency Disorders.

The journal of allergy and clinical immunology. In practice
2020

A systems-level framework for anti-epilepsy drug discovery.

Neuropharmacology
2019

Pharmacological Treatments for Fragile X Syndrome Based on Synaptic Dysfunction.

Current pharmaceutical design
2019

De novo NSF mutations cause early infantile epileptic encephalopathy.

Annals of clinical and translational neurology
2019

A novel lethal recognizable polymicrogyric syndrome caused by ATP1A2 homozygous truncating variants.

Brain : a journal of neurology
2020

Impact on Clinical Decision Making of Next-Generation Sequencing in Pediatric Epilepsy in a Tertiary Epilepsy Referral Center.

Clinical EEG and neuroscience
2020

Pharmacological approaches to tackle NCLs.

Biochimica et biophysica acta. Molecular basis of disease
2021

New avenues in molecular genetics for the diagnosis and application of therapeutics to the epilepsies.

Epilepsy &amp; behavior : E&amp;B
2019

Tackling Epilepsy With High-definition Precision Medicine: A Review.

JAMA neurology
2019

Pathogenic WDFY3 variants cause neurodevelopmental disorders and opposing effects on brain size.

Brain : a journal of neurology
2019

Genetics of neonatal-onset epilepsies.

Handbook of clinical neurology
2019

DEGS1 variant causes neurological disorder.

European journal of human genetics : EJHG
2019

Biallelic mutations in PIGP cause developmental and epileptic encephalopathy.

Annals of clinical and translational neurology
2020

Genetics of neonatal onset epilepsies: An overview.

Revue neurologique
2019

Mouse Models of Familial Hemiplegic Migraine for Studying Migraine Pathophysiology.

Current neuropharmacology
2019

De novo SCN1A, SCN8A, and CLCN2 mutations in childhood absence epilepsy.

Epilepsy research
2019

Stiripentol protects against calcium oxalate nephrolithiasis and ethylene glycol poisoning.

The Journal of clinical investigation
2019

Contribution of ultrarare variants in mTOR pathway genes to sporadic focal epilepsies.

Annals of clinical and translational neurology
2019

Novel ANKRD11 gene mutation in an individual with a mild phenotype of KBG syndrome associated to a GEFS+ phenotypic spectrum: a case report.

BMC medical genetics
2019

Identification of a Loss-of-Function Mutation in the Context of Glutaminase Deficiency and Neonatal Epileptic Encephalopathy.

JAMA neurology
2018

Genome-wide mega-analysis identifies 16 loci and highlights diverse biological mechanisms in the common epilepsies.

Nature communications
2018

[Whole Exome Sequencing in daily practice: the possibilities and impossibilities of this diagnostic test].

Nederlands tijdschrift voor geneeskunde
2018

Multiple Symmetric Lipomatosis (Madelung Disease) in a Large Canadian Family With the Mitochondrial MTTK c.8344A>G Variant.

Journal of investigative medicine high impact case reports
2019

Blood-Brain Barrier: From Physiology to Disease and Back.

Physiological reviews
2018

Exome sequencing in adult neurology practice: Challenges and rewards in a mixed resource setting.

Clinical neurology and neurosurgery
2019

Beta-propeller protein-associated neurodegeneration (BPAN) as a genetically simple model of multifaceted neuropathology resulting from defects in autophagy.

Reviews in the neurosciences
2018

A novel FBXO28 frameshift mutation in a child with developmental delay, dysmorphic features, and intractable epilepsy: A second gene that may contribute to the 1q41-q42 deletion phenotype.

American journal of medical genetics. Part A
2018

To diet or not to diet in neonatal diabetes responding to sulfonylurea treatment.

Journal of pediatric endocrinology &amp; metabolism : JPEM
2018

Identification of new risk factors for rolandic epilepsy: CNV at Xp22.31 and alterations at cholinergic synapses.

Journal of medical genetics
2018

Electrocorticographic telemetric recording in unrestrained mouse pups.

Journal of neuroscience methods
2018

Expansions of intronic TTTCA and TTTTA repeats in benign adult familial myoclonic epilepsy.

Nature genetics
2018

Targeted gene panel and genotype-phenotype correlation in children with developmental and epileptic encephalopathy.

Epilepsy research

Associações

Organizações que acompanham esta doença — pra ter apoio e orientação

Ainda não temos associações cadastradas para Doença monogênica com epilepsia.

É de uma associação que acompanha esta doença? Fale com a gente →

Comunidades

Grupos ativos de quem convive com esta doença aqui no Raras

Ainda não existe comunidade no Raras para Doença monogênica com epilepsia

Pacientes, familiares e cuidadores se organizam em comunidades pra compartilhar experiências, fazer perguntas e se apoiar. Você pode ser o primeiro.

Tire suas dúvidas

Perguntas, dicas e experiências compartilhadas aqui na página

Participe da discussão

Faça login para postar dúvidas, compartilhar experiências e interagir com especialistas.

Fazer login

Doenças relacionadas

Doenças com sintomas parecidos — ajudam quem ainda está buscando diagnóstico

Ordenadas pelo número de sintomas em comum.

Referências e fontes

Bases de dados externas citadas neste artigo

Publicações científicas

Artigos indexados no PubMed ligados a esta doença no grafo RarasNet — título, periódico e PMID direto da fonte, sem intermediação de IA.

  1. Characterizing SCN1A -Related Disorders Using Real-World Data Across 681 Patient-Years.
    medRxiv : the preprint server for health sciences· 2026· PMID 41867217mais citado
  2. Mitochondrial Dysfunction in Monogenic Developmental and Epileptic Encephalopathies.
    Pediatric neurology· 2026· PMID 41825261mais citado
  3. Research progress in SYNGAP1-related neurodevelopmental disorders: from pathogenesis to therapeutic strategies.
    Frontiers in neurology· 2026· PMID 41767012mais citado
  4. International Clinical Evidence-based Guideline for Kleefstra Syndrome.
    Genetics in medicine : official journal of the American College of Medical Genetics· 2026· PMID 41578867mais citado
  5. Seizure outcomes after VNS therapy in children with drug-resistant epilepsy due to monogenic etiologies versus malformations of cortical development.
    Journal of neurosurgery. Pediatrics· 2026· PMID 41569727mais citado
  6. Molecular Profiling of Polish Pediatric Patients with Epilepsy: A Single-Center Diagnostic Experience Using Next-Generation Sequencing.
    Genes (Basel)· 2026· PMID 41751517recente
  7. Altered Auditory Maturation in Fragile X Syndrome and Its Involvement in Audiogenic Seizure Susceptibility.
    Autism Res· 2026· PMID 41399120recente
  8. Genetic Variants and Disease Mechanisms: Lessons from Monogenic Childhood Epilepsies.
    Neuropediatrics· 2026· PMID 41145126recente
  9. Clinical and genetic landscape of epilepsies with absence seizures and single-gene etiology.
    Epilepsia· 2026· PMID 41137852recente

Bases de dados e fontes oficiais

Identificadores e referências canônicas usadas para montar este verbete.

  1. ORPHA:166472(Orphanet)
  2. MONDO:0015653(MONDO)
  3. Epilepsia(PCDT · Ministério da Saúde)
  4. GARD:20086(GARD (NIH))
  5. Variantes catalogadas(ClinVar)
  6. Busca completa no PubMed(PubMed)
  7. Q55785628(Wikidata)

Dados compilados pelo RarasNet a partir de fontes abertas (Orphanet, OMIM, MONDO, PubMed/EuropePMC, ClinicalTrials.gov, DATASUS, PCDT/MS). Este conteúdo é informativo e não substitui avaliação médica.

Conteúdo mantido por Agente Raras · Médicos e pesquisadores podem colaborar

Doença monogênica com epilepsia
Compêndio · Raras BR

Doença monogênica com epilepsia

ORPHA:166472 · MONDO:0015653
🇧🇷 Brasil SUS
Geral
MedGen
UMLS
C5680430
Repurposing
14 candidatos
aminohydroxybutyric-acidcarbonic anhydrase inhibitor
diclofenamidesuccinimide antiepileptic
ethosuximideglutamate receptor antagonist
+11 outros
Wikidata
DiscussaoAtiva

Nenhuma novidade ainda. O agente esta monitorando.

0membros
0novidades